Sotac Pharmaceuticals Past Earnings Performance
Past criteria checks 4/6
Sotac Pharmaceuticals has been growing earnings at an average annual rate of 46.6%, while the Pharmaceuticals industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 19.8% per year. Sotac Pharmaceuticals's return on equity is 7.3%, and it has net margins of 4.1%.
Key information
46.6%
Earnings growth rate
42.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 19.8% |
| Return on equity | 7.3% |
| Net Margin | 4.1% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses Breakdown
How Sotac Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,038 | 43 | 40 | 0 |
| 31 Dec 23 | 955 | 31 | 40 | 0 |
| 30 Sep 23 | 894 | 25 | 43 | 0 |
| 30 Jun 23 | 826 | 27 | 44 | 0 |
| 31 Mar 23 | 775 | 23 | 43 | 0 |
| 31 Mar 22 | 732 | 29 | 30 | 0 |
| 31 Mar 21 | 488 | -24 | 32 | 0 |
| 31 Mar 20 | 286 | 1 | 17 | 0 |
Quality Earnings: SOTAC has a high level of non-cash earnings.
Growing Profit Margin: SOTAC's current net profit margins (4.1%) are higher than last year (3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SOTAC's earnings have grown significantly by 46.6% per year over the past 5 years.
Accelerating Growth: SOTAC's earnings growth over the past year (87.3%) exceeds its 5-year average (46.6% per year).
Earnings vs Industry: SOTAC earnings growth over the past year (87.3%) exceeded the Pharmaceuticals industry 18.2%.
Return on Equity
High ROE: SOTAC's Return on Equity (7.3%) is considered low.